ReviewImmunity, inflammation and disease2026
From Mechanism to Management: The Link Between Inflammatory Bowel Disease and Cardiovascular Disease.
Review in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory bowel diseases (IBDs) constituting the ulcerative colitis (UC) and Crohn's disease (CD) primarily affect the gastrointestinal tract and have been associated with the development of cardiovascular disease (CVDs). To strengthen this further, the focus of our narrative review is to highlight the clinical significance of understanding this association.
methodsWe conducted a narrative review to discuss the mechanisms of pathogenesis underlying the link between the management of inflammatory bowel disease and cardiovascular disease. DISCUSSION: The pathogenesis of the link likely involves dysregulated immune responses leading to overactivation of pro-inflammatory cytokines, suggesting a shared inflammatory pathway. Both diseases share common risk factors such as obesity, diabetes, and gender. Genetic factors, including mutations in NOD2 and CDKN2A, also play a role in the overlap between IBDs and CVDs. Despite the recent developments, conventional cardiovascular risk assessment tools may not fully capture the potential elevated cardiovascular threat in IBD patients.
conclusionThus, proactive investigation with advanced diagnostic tools such as coronary artery calcium (CAC) scoring is crucial in reducing cardiovascular morbidity and mortality in these patients. Nevertheless, future research is needed to further clarify disease activity and its correlations. CLINICAL TRIALS REGISTRATION: NA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.